ADMA Biologics, Inc. (NASDAQ:ADMA) Short Interest Down 8.8% in March

ADMA Biologics, Inc. (NASDAQ:ADMA) was the target of a large decline in short interest in the month of March. As of March 31st, there was short interest totalling 7,290,000 shares, a decline of 8.8% from the March 15th total of 7,990,000 shares. Based on an average trading volume of 2,750,000 shares, the short-interest ratio is presently 2.7 days.

ADMA Biologics Stock Up 3.0 %

Shares of ADMA opened at $6.16 on Wednesday. The firm has a market cap of $1.41 billion, a P/E ratio of -47.62 and a beta of 0.46. The stock has a 50 day simple moving average of $5.88 and a two-hundred day simple moving average of $4.71. The company has a debt-to-equity ratio of 1.04, a current ratio of 5.16 and a quick ratio of 1.69. ADMA Biologics has a 1 year low of $3.06 and a 1 year high of $6.76.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings data on Wednesday, February 28th. The biotechnology company reported $0.04 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.02. The firm had revenue of $73.90 million during the quarter, compared to analyst estimates of $73.50 million. ADMA Biologics had a positive return on equity of 0.49% and a negative net margin of 10.94%. On average, analysts forecast that ADMA Biologics will post 0.3 earnings per share for the current fiscal year.

Insider Activity at ADMA Biologics

In related news, Director Steve Elms sold 49,887 shares of the business’s stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $6.01, for a total value of $299,820.87. Following the sale, the director now directly owns 2,527,500 shares in the company, valued at approximately $15,190,275. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In the last three months, insiders have sold 639,895 shares of company stock worth $3,927,169. Company insiders own 5.90% of the company’s stock.

Institutional Trading of ADMA Biologics

A number of institutional investors have recently made changes to their positions in the stock. BlackRock Inc. boosted its stake in shares of ADMA Biologics by 8.5% during the first quarter. BlackRock Inc. now owns 16,391,319 shares of the biotechnology company’s stock valued at $54,255,000 after purchasing an additional 1,290,038 shares during the period. State Street Corp boosted its stake in shares of ADMA Biologics by 18.0% during the first quarter. State Street Corp now owns 12,988,589 shares of the biotechnology company’s stock valued at $42,992,000 after purchasing an additional 1,981,380 shares during the period. Vanguard Group Inc. boosted its stake in shares of ADMA Biologics by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 12,891,875 shares of the biotechnology company’s stock valued at $58,271,000 after purchasing an additional 110,180 shares during the period. Nuveen Asset Management LLC raised its holdings in shares of ADMA Biologics by 6.3% during the fourth quarter. Nuveen Asset Management LLC now owns 11,355,477 shares of the biotechnology company’s stock valued at $51,327,000 after acquiring an additional 669,543 shares in the last quarter. Finally, Stonepine Capital Management LLC raised its holdings in shares of ADMA Biologics by 1.3% during the fourth quarter. Stonepine Capital Management LLC now owns 9,222,617 shares of the biotechnology company’s stock valued at $41,686,000 after acquiring an additional 118,342 shares in the last quarter. Hedge funds and other institutional investors own 75.68% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Cantor Fitzgerald upped their price target on ADMA Biologics from $6.50 to $8.00 and gave the company an “overweight” rating in a research report on Thursday, February 29th. Mizuho upped their price target on ADMA Biologics from $9.00 to $10.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Finally, HC Wainwright reiterated a “buy” rating and set a $7.50 price target (up from $6.00) on shares of ADMA Biologics in a research report on Tuesday, March 26th. One investment analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $7.88.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.